Ventilator-Associated Pneumonia

Ventilator associated pneumonia

Ventilator associated pneumonia (VAP) is the most common nosocomial infection in patients receiving mechanical ventilation, and it accounts for about half of all antibiotics given in the intensive care unit. Between 250,000 and 300,000 cases per year occur in the United States alone, which is an incidence rate of 5 to 10 cases per 1,000 hospital admissions. The mortality attributable to VAP has been reported up to 50%.

TGV Therapeutics’ lead product is a nebulized Mul-1867 solution designed for convenient self-administration.  Mul-1867 (original nano-sized molecule 1.5-2.0 nm) the first inhaled antimicrobial being developed against multidrug-resistant bacteria and fungi and will be the breakthrough in war with lung infections in patients with VAP.

a4 new

Mul-1867 is effective in chronic and acute lung infections of any origin among patients with VAP.